Anabolic Steroids in Muscle Wasting Conditions

Introduction to Anabolic Steroids

The American College of Clinical Nutrition recommends that both nandrolone and oxandrolone lack sufficient evidence to support routine clinical use in muscle wasting conditions, but when anabolic steroids are considered, oxandrolone is the only FDA-approved option for specific indications and demonstrates a superior safety profile, particularly regarding hepatotoxicity 1, 2, 3, 4

Nandrolone decanoate is administered intramuscularly at 200 mg per week, requiring injection every 1-2 weeks, limiting patient convenience 1, 2, 3, 4
Nandrolone decanoate improved anemia in 30-60% of myelofibrosis patients 5
Oxandrolone is administered orally at 20 mg per day 1, 2, 3, 4

In 37 NSCLC patients undergoing chemotherapy, nandrolone decanoate showed only a trend toward smaller weight loss with no statistically significant benefit 1, 2, 3, 4
The ESPEN guidelines explicitly state insufficient evidence to recommend either agent for increasing muscle mass in cancer patients 1, 2, 3, 4
Nandrolone increased lean mass by 1.7 kg vs 0.3 kg in placebo but failed to improve functional measures like 6-minute walk distance or inspiratory pressure 6
The ACCP/AACVPR guidelines concluded that current evidence does not support routine use of anabolic agents in pulmonary rehabilitation 6

Both agents suppress endogenous testosterone production and gonadotropins, which may persist months after withdrawal, and carry virilization risks in women and children 5

Danazol (400-600 mg daily) may be preferable to nandrolone for anemia in myelofibrosis, with similar 35% response rate but less toxicity 5
Selective androgen receptor modulators (SARMs) are investigational and not yet approved for clinical use 1, 2, 3, 4

Neither agent improves functional outcomes (strength, exercise capacity, quality of life) despite increasing lean body mass in most studies 1, 2, 6, 3, 4